Alpharadin (radium-223)

///Alpharadin (radium-223)

Not All Men Benefit From Radium-223 (Xofigo)?

Researchers are now beginning to understand which men with castration-resistant prostate cancer (CRPC) might be helped by radium-223 (Xofigo), and for which men Xofigo will be a waste of time and money, and possibly cause harm.

They have found that baseline ECOG performance status, alkaline phosphatase (ALP), hemoglobin (Hb) levels, and the concomitant use of abiraterone acetate (Zytiga) or denosumab were indicators for improved overall survival (OS) when radium-223 is used. These findings came from a phase IIIb follow-up to the pivotal phase III ALSYMPCA trial presented at the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC).

Data from the post-hoc analysis showed an improved […]

Chemotherapy After Radium-223 Appears to be Safe in Men with Metastatic Castration-Resistant Prostate Cancer


Understanding how to best sequence and combine our new drugs to treat advanced prostate cancer includes the most discussed issue, efficacy. We want to know if a special order or a special combination of the approved drugs will nake a difference in both our quality of life (QoL) as well as how survival. Often left out of this conversation is safety, will the order we take our drugs or in what combination affect the our safety? We know that many of our new drugs cause cross-resistance to the next drug, however we rarely ask about the potential toxic effects that […]

Radium-223 When Given In Combinations May Improve Survival in mCRPC

As I have said before, the next big step in the clinical care of men with prostate cancer will be in not in the development of a new drug, but in our growing knowledge of how to sequence and combine our new drugs. Today’s post provides just one example of this new type of breakthrough we can look forward to in the near future.

In a recently released phase IIIb study of Radium-223 dichloride (Xofigo) that was given with concomitant medication, there was an improvement in overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) who also had bone […]

Xofigo Without A Co-Pay For Men Who Are Uninsured or Who Have A Medical Policy That Doesn’t Cover Xofigo

I have been informed that it is now possible for men in need of the treatment Xofigo to obtain it without having to pay any co-pays.  The program that is making this possible is called Xofigo Access Services and is designed to make Xofigo available for men with a commercial medical insurance policy (not medicaid or medicare)  that doesn’t cover the cost of Xofigo or who are uninsured.

For more information about this program or to find out where Xofigo is available you can call 1-855-696-3446 and speak to a representative from 9:00 AM to 8:00 PM Monday through Friday.

Xofigo is […]